StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $2.04 | $2.03 | -0.49% | 0.6M |
| 05-14 | $2.04 | $2.04 | +0.00% | 0.4M |
| 05-15 | $2.00 | $2.03 | +1.50% | 0.5M |
| 05-18 | $2.04 | $2.00 | -1.96% | 0.8M |
| 05-19 | $1.98 | $1.96 | -1.01% | 0.6M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2022 2022-12-31 | Annual 2021 2021-12-31 | Annual 2020 2020-12-31 | Q3 2020 2020-09-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $1.18M | $1.18M |
Operating Income | $-127.44M | $-83.56M | $-43.66M | $-25.84M |
Net Income | $-123.48M | $-83.46M | $-45.74M | $-26.97M |
EPS (Diluted) | $-3.03 | $-2.07 | $-2.76 | Not available |
Total Assets | $306.49M | $380.18M | $436.05M | $262.45M |
Total Liabilities | $43.02M | $17.13M | $6.21M | $10.43M |
Cash & Equivalents | $48.82M | $363.67M | $434.22M | $259.48M |
Free Cash Flow OCF − CapEx | $-90.65M | $-68.77M | $-38.32M | $-24.69M |
Shares Outstanding | 40.86M | 40.59M | 39.84M | 37.11M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.